Wydanie specjalne czerwiec 2015
str. 36
Zastosowanie afliberceptu w leczeniu obrzęku plamki wtórnego do zakrzepu żyły centralnej siatkówki – opis przypadków
Aflibercept in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion – Case Reports
Anna I. Borucka, Elżbieta Sidorowicz
Centrum Okulistyczne LASER w Warszawie
Summary: Retinal vein occlusion is the second cause of permanent deterioration of visual acuity of vascular origin, following diabetic retinopathy. Central retinal vein occlusion is a less common form of vein obstruction, but it leads to more advanced complications. The closure of a vein stimulates an inflammation process leading to an increase in release of a number of inflammatory substances and proangiogenic factors, mainly a vascular endothelial growth factor. The most common cause of loss of sight among patients with central retinal vein occlusion is macular edema. The objective of this article is to present patients with macular edema in the course of central retinal vein occlusion treated with intravitreal injections of an anti-VEGF agent – aflibercept. We described three patients aged between 39 and 78 years during observation lasting from 5 months to over 1 year. In two patients, despite the treatment, no long term improvement of activity or morphology was observed. A reason for temporary effects of treatment with aflibercept in case of those patients may be lack of regularity in coming for check-ups, the use of PRN (“pro re nata”) from the beginning of the treatment and numerous general diseases, as well as disorders in blood coagulation system.
Słowa kluczowe: zakrzep żyły centralnej siatkówki, obrzęk plamki, aflibercept.
Keywords: central retinal vein occlusion, macular edema, aflibercept.